QualityStocks would like to highlight China Botanic Pharmaceutical Inc. (NYSE: CBP). The company researches, develops, manufactures, and distributes botanical products, bio-pharmaceutical products, and traditional Chinese medicines in the Peoples Republic of China. It offers botanical anti-depression and nerve-regulation products, including Acanthopanax, a Siberian ginseng that regulates the nervous system, delays aging process, strengthens the body, and treats neurasthenia, insomnia, cerebrovascular and cardiovascular diseases, and fatigue; Tianma tablets and compound Yangjiao tablets, which are botanic drugs for treating headaches and regulate nerves; and compound Schisandra tablets, a botanic drug used to regulate central nervous system, generate body fluids and alleviate thirst, nourish the kidneys, and cure insomnia and palpitations, as well as to cure neurasthenia.
In the company’s news yesterday,
China Botanic Pharmaceutical recently announced that the State Intellectual Property Office of the People’s Republic of China (SIPO) will be granting the company a new invention patent on its comprehensive method to enhance the medicinal value of Schisandra, a key component in its pharmaceutical products. The company expects to receive the patent certificate by October 2012.
China Botanic filed Patent Application No: 201010119861.3 in February 2010, which was followed by a two-year comprehensive review conducted by the SIPO. Upon grant of the new patent, the company anticipates securing market exclusivity for a period of 20 years.
Research in China suggests that Schisandra is a wild plant with significant medical and health benefits. Schisandra has been found to prevent liver damage and is an effective sedative for treating insomnia and central nervous system depression. China Botanic’s comprehensive method enables it to obtain a number of compounds out of Schisandra, including lignin, polysaccharides, vitamins, and organic acids.
China Botanic’s Chairman and CEO, Mr. Shaoming Li, remarked, “Schisandra is one of the important components for our anti-depression and nervous system regulating products. We look forward to receiving the new patent in October, which will further support our research and development of Schisandra, development of Schisandra-based new medicines and strengthen our ability to leverage the potential of Schisandra. In addition, our continued success in obtaining new patents and our commitment to invest into research, development and talent defines our long-term growth strategy. We believe that in the foreseeable future, our new patent will favorably contribute to our business performance.”
About QualityStocks
QualityStocks, based in Scottsdale, Arizona, is a free service that collects data from hundreds of Small-Cap and Micro-Cap online Investment Newsletters into one Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their investor communication efforts and connecting subscribers with companies that have huge potential to succeed in the short and long-term future.
To sign up for The QualityStocks Daily Newsletter, please visit www.QualityStocks.net
Please read FULL disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.net
Forward-Looking Statement:
This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.
